Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant plus radiotherapy vs placebo in high-risk resected LA SCCHN ineligible for cisplatin
CTR20222569Phase 3Terminated
- Sponsor
- Not applicable
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xevinapant in head and neck squamous cell carcinoma (HNSCC), sponsored by Not applicable. Started Oct 2022; status: terminated.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20222569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222569.